Journal Mobile Options
Table of Contents
Vol. 4, No. 6, 2007
Issue release date: October 2007

Peripheral Inflammatory Cytokines as Biomarkers in Alzheimer’s Disease and Mild Cognitive Impairment

Guerreiro R.J. · Santana I. · Brás J.M. · Santiago B. · Paiva A. · Oliveira C.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Several lines of evidence in the literature have shown that inflammation is involved in the pathogenesis of Alzheimer’s disease (AD). However, the results from the evaluation of serum inflammatory markers in AD patients have been controversial. Objective: To determine if any differences exist in the monocytic secretion pattern of IL-1β, IL-6, IL-12 and TNF-α from mild cognitive impairment (MCI) and AD patients, when compared with healthy age-matched controls. Methods: To evaluate the percentage of peripheral monocytes secreting IL-1β, IL-6, IL-12 and TNF-α along with the relative levels of these proteins, a cytofluorimetric analysis was conducted under basal conditions and after lipopolysaccharide-induced cell activation. Results: We found, in AD and MCI patients, a significant raise in the percentage of monocytes producing the studied cytokines (under basal conditions and after the exposure to an inflammatory stimulus), as well as a decreased competence of these cells to respond to inflammatory challenges, when compared with controls. Conclusions: These results agree with a persistent inflammatory status in AD, reinforcing the hypothesis of a progressive impairment of the immune response in this disorder and suggesting that monocytes may be good targets to study the progression from MCI to AD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Scarpini E, Cogiamanian F: Alzheimer’s disease: from molecular pathogenesis to innovative therapies. Expert Rev Neurother 2003;3:619–630.
  2. Wenk GL: Neuropathologic changes in Alzheimer’s disease. J Clin Psychiatry 2003;64(suppl 9):7–10.

    External Resources

  3. Lorton D, Kocsis JM, King L, Madden K, Brunden KR: Beta-amyloid induces increased release of interleukin-1β from lipopolysaccharide-activated human monocytes. J Neuroimmunol 1996;67:21–29.
  4. Meda L, Cassatella M, Szendrei G, Otvos L, Baron P, Villaba M, Ferrari D, Rossi F: Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 1995;374:647–650.
  5. Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LME: Increased plasma levels of interleukin-1, interleukin-6 and α1-antichymotrypsin in patients with Alzheimer’s disease: peripheral inflammation or signals from the brain? J Neuroimmunol 2000;103:97–102.
  6. Forloni G, Mangiarotti F, Angeretti N, Lucca E, De Simoni MG: Beta-amyloid fragment potentiates IL-6 and TNF-α secretion by LPS in astrocytes but not in microglia. Cytokine 1997;9:759–762.
  7. Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P: Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients. Neurol Sci 2006;27:33–39.
  8. Bauer J, Strauss S, Schreiter-Gasser U, et al: IL-6 and α2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices. FEBS Lett 1991;285:111–114.
  9. Griffin WS, Stanley L, Ling C, et al: Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989;86:7611–7615.
  10. Song D, Im Y, Jung J, Cho J, Suh H, Kim Y: Central β-amyloid peptide-induced peripheral interleukin-6 responses in mice. J Neurochem 2001;76:1326–1335.
  11. Galasko D: Cerebrospinal fluid biomarkers in Alzheimer disease. Arch Neurol 2003;60:1195–1196.
  12. Graff-Radford N, Ertekin-Taner N, Jadeja N, Younkin LH, Petersen R, Younkin S: Evidence that plasma amyloid β protein may be useful as a premorbid biomarker for Alzheimer’s disease. Neurobiol Aging 2002;23:S384.

    External Resources

  13. Ripova D, Strunecka A: An ideal biological marker of Alzheimer’s disease: dream or reality? Physiol Res 2001;50:119–129.
  14. Turner RS: Biomarkers of Alzheimer’s disease and mild cognitive impairment: Are we there yet? Exp Neurol 2003;183:7–10.
  15. Richartz E, Batra A, Simon P, Wormstall H, Bartels M, Buchkremer G, Schott K: Diminished production of proinflammatory cytokines in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2005;19:184–188.
  16. Sala G, Galimberti G, Canevari C, Raggi ME, Isella V, Facheris M, Appollonio I, Ferrarese C: Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol Aging 2003;24:909–914.
  17. Diagnostic and Statistical Manual of Mental Disorders – DSM-IV, ed 4. Washington, American Psychiatric Association, 1994.
  18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  19. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  20. Berg L: Clinical dementia rating. Psychopharmacol Bull 1988;24:637–639.
  21. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST: Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133–1142.
  22. Maino VC, Picker LJ: Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry 1998;34:207–215.
  23. Bueno C, Almeida J, Alguero MC, Sanchez ML, Vaquero JM, Laso FJ, San Miguel JF, Escribano L, Orfao A: Flow cytometric analysis of cytokine production by normal human peripheral blood dendritic cells and monocytes: comparative analysis of different stimuli, secretion-blocking agents and incubation periods. Cytometry 2001;46:33–40.
  24. Bueno C, Rodriguez-Caballero A, Garcia-Montero A, Pandiella A, Almeida J, Orfao A: A new method for detecting TNF-α-secreting cells using direct-immunofluorescence surface membrane stainings. J Immunol Methods 2002;264:77–87.
  25. Schuerwegh AJ, Stevens WJ, Bridts CH, De Clerck LS: Evaluation of monensin and brefeldin A for flow cytometric determination of interleukin-1β, interleukin-6, and tumor necrosis factor-α in monocytes. Cytometry 2001;46:172–176.
  26. Alvarez X, Franco A, Fernandez-Novoa L, Cacabelos R: Blood levels of histamine, IL-1β, and TNF-α in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol 1996;29:237–252.
  27. Singh VK, Guthikonda P: Circulating cytokines in Alzheimer’s disease. J Psychiatr Res 1997;31:657–660.
  28. Tarkowski E, Blennow K, Wallin A, Tarkowski A: Intracerebral production of TNF-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999;19:223–230.
  29. Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhoj P, Pedersen BK: A high plasma concentration of TNF-α is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci 1999;54:M357–M364.
  30. Huberman M, Sredni B, Stern L, Kott E, Shalit F: IL-2 and IL-6 secretion in dementia: correlation with type and severity of disease. J Neurol Sci 1995;130:161–164.
  31. Bonaccorso S, Lin A, Song C, Verkerk R, Kenis G, Bosmans E, Scharpe S, Vandewoude M, Dossche A, Maes M: Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer’s disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT. Aging (Milano) 1998;10:316–323.
  32. Fillit H, Ding W, Buee L, et al: Elevated circulating TNF levels in Alzheimer’s disease. Neurosci Lett 1991;129:318–320.
  33. Bauer J, Ganter U, Strauss S, Stadtmuller G, Frommberger U, Bauer H, Volk B, Berger M: The participation of interleukin-6 in the pathogenesis of Alzheimer’s disease. Res Immunol 1992;143:650–657.
  34. Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk B: Detection of interleukin-6 and α2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer’s disease patients. Lab Invest 1992;66:223–230.
  35. Lombardi VR, Garcia M, Rey L, Cacabelos R: Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer’s disease individuals. J Neuroimmunol 1999;97:163–171.
  36. Cacabelos R, Barquero M, Garcia P, Alvarez XA, Varela de Seijas E: Cerebrospinal fluid interleukin-1β in Alzheimer’s disease and neurological disorders. Methods Find Exp Clin Pharmacol 1991;13:455–458.
  37. Hampel H, Schoen D, Schwarz M, et al: IL-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer’s disease. Neurosci Lett 1997;228:143–146.
  38. Marz P, Heese K, Hock C, Golombowski S, Muller-Spahn F, Rose-John S, Otten U: IL-6 and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer’s disease patients. Neurosci Lett 1997;239:29–32.
  39. Davis E, Foster T, Thomas W: Cellular forms and functions of brain microglia. Brain Res Bull 1994;34:73–78.
  40. Gehrman J, Banati R: Microglial turnover in the injured CNS: activated microglia undergo delayed DNA fragmentation following peripheral nerve injury. J Neuropath Exp Neurol 1995;54:680–688.
  41. Kim S, Vellis J: Microglia in health and disease. J Neurosci Res 2005;81:302–313.
  42. De Simoni MG, Sironi M, De Luigi A, Manfridi A, Mantovani A, Ghezzi P: Intracerebroventricular injection of interleukin-1 induces high circulating levels of interleukin-6. J Exp Med 1990;171:1773–1778.
  43. De Simoni MG, Del Bo R, De Luigi A, Simard S, Forloni G: Central endotoxin induces different patterns of IL-1β and IL-6 messenger ribonucleic acid expression and IL-6 secretion in the brain and periphery. Endocrinology 1995;136:897–902.
  44. De Luigi A, Terreni L, Sironi M, De Simoni MG: The sympathetic nervous system tonically inhibits peripheral interleukin-1β and interleukin-6 induction by central lipopolysaccharide. Neuroscience 1998;83:1245–1250.
  45. De Luigi A, Pizzimenti S, Quadri P, Lucca U, Tettamanti M, Fragiacomo C, De Simoni MG: Peripheral inflammatory response in Alzheimer’s disease and multi-infarct dementia. Neurobiol Dis 2002;11:308–314.
  46. In ’t Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH: Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001;345:1515–1521.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50